Eli Lilly & Co. (LLY): If You’re Going to Fail, Fail Quickly

Lilly calls active as shares soar; Put spreads constructed on Verizon, AT&TIn goes another drug into the Eli Lilly & Co. (NYSE:LLY) trash can. The pharma is dropping development of tabalumab for rheumatoid arthritis.

It’s not particularly surprising given that the drug failed a phase 3 trial in December, but it’s still disappointing for a company that could really use a positive result. Tabalumab joins in the trash can Alimta for lung cancer, pomaglumetad methionil for schizophrenia, and Forteo for back pain, which all recently failed clinical trials.

The trial results released in December showed that tabalumab failed to help patients who didn’t respond to methotrexate, a drug typically used early in disease progression. Based on that result, Eli Lilly decided to take an early look at its other study in patients who failed to respond to one or more tumor necrosis factor inhibitors — AbbVie Inc (NYSE:ABBV)‘s Humira, Johnson & Johnson (NYSE:JNJ) and Merck & Co., Inc. (NYSE:MRK)‘s Remicade, or Pfizer Inc. (NYSE:PFE) and Amgen, Inc. (NASDAQ:AMGN)‘s Enbrel — that are typically used later in the progression of rheumatoid arthritis. The interim peek at the data showed that it was futile to continue, so Lilly has decided to drop development of tabalumab in rheumatoid arthritis.

While Humira, Remicade, and Enbrel are safe from future competition from tabalumab, GlaxoSmithKline plc (ADR) (NYSE:GSK) still needs to watch its back. Eli Lilly is continuing development of tabalumab as a treatment for lupus. The drug attacks the same target — B cell activating factor, or BAFF — as Glaxo’s Benlysta, so the chance of success is higher for lupus.

Glaxo and its acquired partner Human Genome Sciences tested Benlysta on rheumatoid arthritis where it was shown to be ineffective, so it shouldn’t come as much of a surprise that tabalumab was ineffective as well.

I’m not sure exactly what led Lilly to believe it could succeed where Benlysta had failed, perhaps it felt tabalumab was a better inhibitor and could therefore succeed. Hindsight is 20/20, but it seems likely that BAFF isn’t a good target for rheumatoid arthritis. The only good decision we can say Lilly made in the development of tabalumab for rheumatoid arthritis is that it ended development early, saving money by not letting the trials go to completion before realizing that it was a dead end.

The article If You’re Going to Fail, Fail Quickly originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click here to Read Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 74 percentage points in 2.5 years. Our beta is only 1.2 (download a FREE newsletter and see the details inside)

Lists

Best Selling Magazines in the World

Shortest People in History

The Most Celebrated Holidays in the World

Most Expensive Handbag Brands in the World

Top Selling Comic Book Issues of this Century

The Most Powerful Women in Politics

Best Paid DJs

Most Rebellious Female Artists

Best Paid TV Actresses of 2014

Best Paid Actors of 2014

Most Expensive Horses in the World

Tallest People Ever

Most Encouraging Feminist Celebrities

Best Paid Supermodels of 2014

Top 10 Suburbs for Retirement in 2015

10 Wealthiest Cities in America

Top 10 TED Talks for Entrepreneurs

Best TED Talks on Education

25 Most Dangerous Places to Live in America

Top 10 Ski Resorts in the United States – 2014 List

Top 10 Most Remote Places in the World

Most Visited Museums in the United States

Wealthiest Photographers in the World

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!